<DOC>
	<DOCNO>NCT01950585</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) serious eventually fatal disease damage lung heart . It result narrow eventual blockage small blood vessel lung , due abnormal proliferation cell blood vessel ( arterial ) . Patients PAH suffer fatigue , shortness breath , low oxygen level , blood clot heart failure . No therapies reverse disease process lung artery , however three approve drug temporarily dilate vessel improve symptom . However , three drug significant side effect toxicity , work effectively many patient , survival remain average 2 3 year symptoms begin , none drug prevent underlie disease process small artery lung . PAH known develop patient pre-existing class bone marrow diseases call myeloproliferative disorder ( MPDs ) . We others recently show patient PAH bone marrow change similar see patient MPDs , even without sign symptom bone marrow disease anemia high platelet white blood cell count . Compared healthy volunteer , patient PAH high frequency immature stem progenitor cell able produce blood cell vascular wall cell bone marrow . They also higher circulate number cell blood , increase localization cell lung blood vessel . When immature bone marrow cell PAH patient normal volunteer infused mouse , mouse receive PAH marrow cell develop similar lung heart problem PAH patient , suggest bone marrow problem primary cause lung problem , increase number immature bone marrow cell bone marrow blood PAH patient cause lung blood vessel disease . The drug hydroxyurea use inhibit abnormally high level bone marrow cell proliferation patient MPDs . It show reduce number circulate immature bone marrow cell patient MPDs . Hydroxyurea available almost fifty year , use treat patient MPDs , sickle cell anemia , congenital heart disease prolong period time , twenty year individual patient . It excellent long-term safety profile side effect generally well tolerate . It appear result increase rate leukemia even many year treatment . In current protocol , hypothesize treat patient PAH hydroxyurea decrease level circulate immature bone marrow cell interrupt abnormal narrow occlusion lung artery . We treat patient moderately severe primary ( know underlie cause ) PAH 6 month hydroxyurea , carefully monitor side effect adjust dosage necessary , measure effect circulate immature cell , lung blood vessel pressure , blood marker active PAH , exercise tolerance .</brief_summary>
	<brief_title>Hydroxyurea Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Pulmonary arterial hypertension ( PAH ) serious eventually fatal disease damage lung heart . It result narrow eventual blockage small blood vessel lung , due abnormal proliferation cell blood vessel ( arterial ) . Patients PAH suffer fatigue , shortness breath , low oxygen level , blood clot heart failure . No therapies reverse disease process lung artery , however three approve drug temporarily dilate vessel improve symptom . However , three drug significant side effect toxicity , work effectively many patient , survival remain average 2 3 year symptoms begin , none drug prevent underlie disease process small artery lung . PAH known develop patient pre-existing class bone marrow diseases call myeloproliferative disorder ( MPDs ) . We others recently show patient PAH bone marrow change similar see patient MPDs , even without sign symptom bone marrow disease anemia high platelet white blood cell count . Compared healthy volunteer , patient PAH high frequency immature stem progenitor cell able produce blood cell vascular wall cell bone marrow . They also higher circulate number cell blood , increase localization cell lung blood vessel . When immature bone marrow cell PAH patient normal volunteer infused mouse , mouse receive PAH marrow cell develop similar lung heart problem PAH patient , suggest bone marrow problem primary cause lung problem , increase number immature bone marrow cell bone marrow blood PAH patient cause lung blood vessel disease . The drug hydroxyurea use inhibit abnormally high level bone marrow cell proliferation patient MPDs . It show reduce number circulate immature bone marrow cell patient MPDs . Hydroxyurea available almost fifty year , use treat patient MPDs , sickle cell anemia , congenital heart disease prolong period time , twenty year individual patient . It excellent long-term safety profile side effect generally well tolerate . It appear result increase rate leukemia even many year treatment . In current protocol , hypothesize treat patient PAH hydroxyurea decrease level circulate immature bone marrow cell interrupt abnormal narrow occlusion lung artery . We treat patient moderately severe primary ( know underlie cause ) PAH 6 month hydroxyurea , carefully monitor side effect adjust dosage necessary , measure effect circulate immature cell , lung blood vessel pressure , blood marker active PAH , exercise tolerance .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year old Patients idiopathic familial PAH WHO IIIII performance status On PAH medication change stable past two month Seronegative HIV antibody , hepatitis B antigen , hepatitis C antibody . EXCLUSION CRITERIA : Thrombocytopenia platelets less 100,000/mm3 , anemia hemoglobin le 10.5g/dL neutropenia ANC le 1500/mm3 Creatinine &gt; 2.0mg/dL Hepatic insufficiency ( transaminase level &gt; 4 fold upper limit normal bilirubin &gt; 2 fold upper limit normal ) Severe arterial hypertension ( systolic blood pressure &gt; 200mmHg diastolic &gt; 120mmHg ) Female subject nursing pregnant unwilling take oral contraceptive refrain pregnancy childbearing potential Participation investigative treatment study time enrollment Unable understand investigational nature study give inform consent ( i.e . decisionally impaired ) &lt; TAB &gt; Evidence major bleed active infection Known allergy study drug drug similar study drug Subjects know liver cirrhosis chronic active hepatitis . HIV positivity Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient ability tolerate protocol therapy , death within 30 day likely Presence 9 ; 22 BCR/ABL translocation detect conventional bone marrow cytogenetics PCR BCR/ABL transcript , presence JAK2 V617F mutation bone marrow peripheral blood cell . On betablocker therapy require dose adjustment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>October 23, 2014</verification_date>
	<keyword>Hydroxyurea</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Idiopathic Pulmonary Arterial Hypertension</keyword>
	<keyword>Familial Pulmonary Arterial Hypertension</keyword>
	<keyword>CD34 + Cells</keyword>
</DOC>